| Assessment Status | Rapid Review Complete |
| HTA ID | 23019 |
| Drug | Fondaparinux |
| Brand | Arixtra® |
| Indication | Fondaparinux (Arixtra®) is indicated for the prevention of Venous Thromboembolic Events, treatment of Acute coronary syndrome, treatment of Superficial vein thrombosis, treatment of Deep vein thrombosis and acute Pulmonary Embolism. |
| Assessment Process | |
| Rapid review commissioned | 19/04/2023 |
| Rapid review resubmission required | 04/07/2023 |
| Rapid review completed | 28/08/2023 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that fondaparinux not be considered for reimbursement at the submitted price*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
